Streptozocin-treated Verner-Morrison Syndrome: plasma vasoactive intestinal peptide and tumor responses
Department of Medicine, Division of Hematology/Oncology
Adenoma, Islet Cell; Diarrhea; Female; Humans; Hypokalemia; Middle Aged; Pancreatic Neoplasms; Stomach Diseases; Streptozocin; Syndrome; Vasoactive Intestinal Peptide
Life Sciences | Medicine and Health Sciences | Women's Studies
A patient with watery diarrhea, hypokalemia, hypochlorhydria, and a non-beta islet cell carcinoma of the pancreas (Verner-Morrison syndrome) was found to have an elevated vasoactive intestinal peptide (VIP) concentration in the plasma as well as in the tumor. Treatment with streptozocin resulted in a dramatic subjective and objective tumor response in this patient. Plasma VIP concentration fell into the normal range after four courses of treatment, diarrhea ceased after the third course of therapy, and measurable tumor mass markedly decreased during that same period of time. The patient remains in clinical remission with no evidence of tumor regrowth 18 months after the beginning of treatment. In this patient, plasma VIP measurements were an excellent marker of tumor activity and correlated well with objective disease measurements and clinical response.
Rights and Permissions
Citation: Arch Intern Med. 1976 Dec;136(12):1429-35.
Gagel, R. F.; Costanza, Mary E.; DeLellis, R. A.; Norton, R. A.; Bloom, S. R.; Miller, H. H.; Ucci, A.; and Nathanson, L., "Streptozocin-treated Verner-Morrison Syndrome: plasma vasoactive intestinal peptide and tumor responses" (1976). Women’s Health Research Faculty Publications. 82.